DrugPatentWatch Database Preview
Details for Patent: 9,050,302
Which drugs does patent 9,050,302 protect, and when does it expire?
This patent has twelve patent family members in thirteen countries.
Summary for Patent: 9,050,302
Title: | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
Abstract: | One embodiment of the present invention is to improve the safety and efficacy of the administration of GHB or a salt thereof to a patient. It has been discovered that the concomitant administration of an MCT inhibitor, such as diclofenac, valproate, or ibuprofen, will affect GHB administration. For example, it has been discovered that diclofenac lowers the effect of GHB in the body, thereby potentially causing an unsafe condition. Furthermore, it has been discovered that valproate increases the effect of GHB on the body, thereby potentially causing an unsafe condition. |
Inventor(s): | Eller; Mark (Redwood City, CA) |
Assignee: | Jazz Pharmaceuticals Ireland Limited (Dublin, IE) |
Application Number: | 13/837,714 |
Patent Claim Types: see list of patent claims | Use; |
Drugs Protected by US Patent 9,050,302
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Patent Submitted |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jazz Pharms | XYREM | sodium oxybate | SOLUTION;ORAL | 021196-001 | Jul 17, 2002 | AA | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | METHOD OF TREATING EXCESSIVE DAYTIME SLEEPINESS AND/OR CATAPLEXY IN NARCOLEPSY PATIENTS WITH SODIUM OXYBATE WHEN DIVALPROEX SODIUM IS CONCOMITANTLY ADMINISTERED. | ➤ Sign Up | |||
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Patent Submitted |
Non-Orange Book US Patents Family Members for Patent 9,050,302
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
Patent No. | Title | Estimated Patent Expiration |
---|---|---|
9,486,426 | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters | ➤ Sign Up |
8,772,306 | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters | ➤ Sign Up |
8,952,029 | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters | ➤ Sign Up |
Patent No. | Title | Estimated Patent Expiration |
International Patents Family Members for US Patent 9,050,302
Country | Document Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Australia | 2014223373 | ➤ Sign Up | |||
Canada | 2902948 | ➤ Sign Up | |||
China | 105073106 | ➤ Sign Up | |||
Denmark | 2961399 | ➤ Sign Up | |||
Country | Document Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |